Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Angiodynamics (ANGO) Common Equity (2016 - 2026)

Angiodynamics' Common Equity history spans 16 years, with the latest figure at $173.4 million for Q1 2026.

  • For Q1 2026, Common Equity fell 6.73% year-over-year to $173.4 million; the TTM value through Feb 2026 reached $173.4 million, down 6.73%, while the annual FY2025 figure was $183.0 million, 11.0% down from the prior year.
  • Common Equity reached $173.4 million in Q1 2026 per ANGO's latest filing, down from $176.3 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $429.7 million in Q1 2022 to a low of $173.4 million in Q1 2026.
  • Average Common Equity over 5 years is $293.3 million, with a median of $218.7 million recorded in 2024.
  • Peak YoY movement for Common Equity: rose 3.32% in 2023, then crashed 54.05% in 2024.
  • A 5-year view of Common Equity shows it stood at $408.0 million in 2022, then fell by 1.65% to $401.2 million in 2023, then plummeted by 53.45% to $186.8 million in 2024, then decreased by 5.59% to $176.3 million in 2025, then decreased by 1.69% to $173.4 million in 2026.
  • Per Business Quant, the three most recent readings for ANGO's Common Equity are $173.4 million (Q1 2026), $176.3 million (Q4 2025), and $178.9 million (Q3 2025).